RPLP0 and central nervous system cancer: The levels of serum antibodies of CENPF, MIF, M-RIP, RPLP0, TGFBI and UNC45A were significantly lower in patients with high-grade glioma than in those with low-grade glioma (Figure1A-C, E, H and I) and, moreover, the levels of anti-M-RIP and anti-RPLP0 antibodies in patients with high-grade glioma were also significantly lower than in healthy volunteers (Figure1C and E).